Immune profile diversity is achieved with synthetic TLR4 agonists combined with the RG1-VLP vaccine in mice.

Autor: Matthews RL; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Khan N; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Beckman B; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Sharma S; Department of Veterinary Pathobiology and Bond Life Sciences Center, University of Missouri, Columbia, MO, USA., Dietz Z; Department of Veterinary Pathobiology and Bond Life Sciences Center, University of Missouri, Columbia, MO, USA., Picking WD; Department of Veterinary Pathobiology and Bond Life Sciences Center, University of Missouri, Columbia, MO, USA., Izmirlian G; Biometry Research Group, Division of Cancer Prevention, NCI, Bethesda, MD, USA., Sanders C; Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Stocks SM; Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Difilippantonio S; Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kirnbauer R; Laboratory of Viral Oncology (LVO), Department of Dermatology, Medical University of Vienna, Austria., Roden RB; Department of Pathology, Johns Hopkins University, Baltimore, MD, USA., Pinto LA; Vaccine, Immunity, and Cancer Directorate, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Shoemaker RH; Chemopreventive Agent Development Research Group, Division of Cancer Prevention, NCI, Bethesda, MD, USA., Ernst RK; Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA., Marshall JD; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Electronic address: jason.marshall2@nih.gov.

Publikováno v: Vaccine [Vaccine] 2024 Dec 03, pp. 126577. Date of Electronic Publication: 2024 Dec 03.

Improvement of RG1-VLP vaccine performance in BALB/c mice by substitution of alhydrogel with the next generation polyphosphazene adjuvant PCEP.

Autor: Valencia SM; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Zacharia A; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Marin A; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA., Matthews RL; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Wu CK; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Myers B; Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Sanders C; Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Difilippantonio S; Laboratory Animal Sciences Program, Leidos Biomedical Research Inc., Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kirnbauer R; Laboratory of Viral Oncology (LVO), Department of Dermatology, Medical University of Vienna, Austria, EU., Roden RB; Department of Pathology, Johns Hopkins University, Baltimore, MD, USA., Pinto LA; HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Shoemaker RH; Chemopreventive Agent Development Group, Division of Cancer Prevention, NCI, Bethesda, MD, USA., Andrianov AK; Institute for Bioscience and Biotechnology Research, University of Maryland, Rockville, MD, USA., Marshall JD; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA.

Publikováno v: Human vaccines & immunotherapeutics [Hum Vaccin Immunother] 2021 Aug 03; Vol. 17 (8), pp. 2748-2761. Date of Electronic Publication: 2021 Feb 11.

Optimization of RG1-VLP vaccine performance in mice with novel TLR4 agonists.

Autor: Zacharia A; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Harberts E; Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA., Valencia SM; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Myers B; Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Sanders C; Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Jain A; Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, USA., Larson NR; Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, USA., Middaugh CR; Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, USA., Picking WD; Department of Pharmaceutical Chemistry, School of Pharmacy, University of Kansas, Lawrence, KS, USA., Difilippantonio S; Laboratory Animal Sciences Program, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Kirnbauer R; Laboratory of Viral Oncology (LVO), Department of Dermatology, Medical University of Vienna, Austria, EU., Roden RB; Department of Pathology, Johns Hopkins University, Baltimore, MD, USA., Pinto LA; HPV Immunology Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA., Shoemaker RH; Chemopreventive Agent Development Group, Division of Cancer Prevention, NCI, Bethesda, MD, USA., Ernst RK; Department of Microbial Pathogenesis, University of Maryland School of Dentistry, Baltimore, MD, USA., Marshall JD; Cancer ImmunoPrevention Laboratory, Frederick National Laboratory for Cancer Research, Frederick, MD, USA. Electronic address: jason.marshall2@nih.gov.

Publikováno v: Vaccine [Vaccine] 2021 Jan 08; Vol. 39 (2), pp. 292-302. Date of Electronic Publication: 2020 Dec 10.

Prevalence and genotype distribution of human papillomavirus infection among 66000 women from 2014 to 2023 in the plateau region of Southwest China.

Autor: Hu, Jian-Peng¹ (AUTHOR), Wang, Jun-Ling¹ (AUTHOR), Li, Yun² (AUTHOR), Feng, Yuan³ (AUTHOR), Tian, Can-Qiong⁴ (AUTHOR), Zhang, Guo-Hui⁵ (AUTHOR), Chen, Xue-Qin³ (AUTHOR), Liu, Hong-Xia¹ (AUTHOR), Yang, Jin-Si¹ (AUTHOR), Fang, Zhe-Wei¹ (AUTHOR), Li, Yao-Xing⁵ (AUTHOR), Wu, Zong-Sheng¹ (AUTHOR), Zhu, Rui¹ (AUTHOR), Li, Xiu-Ping¹ (AUTHOR), Xiong, Qian¹ (AUTHOR), Gao, Lian-Hao¹ (AUTHOR), Ji, Ting¹ (AUTHOR), Zhang, Jian-Dong¹ (AUTHOR), Song, Jian-Mei¹ (AUTHOR), Chen, Qi¹ (AUTHOR)

Publikováno v: Virology Journal. 8/6/2024, Vol. 21 Issue 1, p1-15. 15p.

Therapeutic Role of HPV Vaccination on Benign HPV-induced Epithelial Proliferations in Immunocompetent and Immunocompromised Patients: Case Study and Review of the Literature.

Autor: Matucci-Cerinic, Caterina^1,2 (AUTHOR) c.matuccicerinic@gmail.com, Herzum, Astrid³ (AUTHOR), Ciccarese, Giulia⁴ (AUTHOR), Rosina, Silvia² (AUTHOR), Caorsi, Roberta^1,2 (AUTHOR), Gattorno, Marco² (AUTHOR), Occella, Corrado³ (AUTHOR), Viglizzo, Gianmaria³ (AUTHOR), Volpi, Stefano^1,2 (AUTHOR) c.matuccicerinic@gmail.com

Publikováno v: Open Forum Infectious Diseases. Jul2024, Vol. 11 Issue 7, p1-7. 7p.